SHUKRA PHARMACEUTICALS
|
SHUKRA PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 11.26 | 4.79 | 1.20 | 0.23 | 2.95 |
| CEPS(Rs) | 15.95 | 3.21 | 2.21 | 2.01 | 1.89 |
| DPS(Rs) | 0.50 | 0.50 | - | - | 0.50 |
| Book NAV/Share(Rs) | 64.63 | 104.43 | 99.63 | 98.43 | 98.20 |
| Tax Rate(%) | 0.79 | 26.26 | -92.33 | 79.16 | 36.22 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.12 | 14.09 | 12.90 | 11.22 | 24.95 |
| EBIT Margin(%) | 8.03 | 6.37 | 1.17 | 1.26 | 10.97 |
| Pre Tax Margin(%) | 7.55 | 4.97 | 0.87 | 1.24 | 10.96 |
| PAT Margin (%) | 7.49 | 3.66 | 1.68 | 0.26 | 6.99 |
| Cash Profit Margin (%) | 10.61 | 11.78 | 14.84 | 11.02 | 21.55 |
| Performance Ratios | |||||
| ROA(%) | 8.01 | 2.12 | 0.54 | 0.11 | 1.76 |
| ROE(%) | 21.16 | 4.70 | 1.21 | 0.23 | 3.04 |
| ROCE(%) | 18.85 | 5.79 | 0.54 | 0.77 | 3.62 |
| Asset Turnover(x) | 1.07 | 0.58 | 0.32 | 0.44 | 0.25 |
| Sales/Fixed Asset(x) | 1.58 | 0.60 | 0.34 | 0.46 | 0.24 |
| Working Capital/Sales(x) | 5.57 | 5.86 | 1.24 | 1.84 | 0.93 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.63 | 1.67 | 2.91 | 2.19 | 4.13 |
| Receivable days | 116.60 | 152.77 | 288.50 | 176.69 | 228.42 |
| Inventory Days | 22.06 | 50.20 | 50.01 | 22.02 | 11.47 |
| Payable days | 172.53 | 245.53 | 761.94 | 562.70 | 872.04 |
| Valuation Parameters | |||||
| PER(x) | 4.17 | 2.62 | 7.71 | 42.79 | 2.58 |
| PCE(x) | 2.94 | 3.92 | 4.19 | 4.84 | 4.02 |
| Price/Book(x) | 0.73 | 0.58 | 0.45 | 0.47 | 0.37 |
| Yield(%) | 1.07 | 0.83 | - | - | 1.37 |
| EV/Net Sales(x) | 0.33 | 0.61 | 1.45 | 1.29 | 2.04 |
| EV/Core EBITDA(x) | 2.97 | 4.23 | 9.02 | 9.84 | 6.83 |
| EV/EBIT(x) | 4.12 | 9.61 | 123.83 | 88.17 | 15.91 |
| EV/CE(x) | 0.26 | 0.36 | 0.46 | 0.45 | 0.41 |
| M Cap / Sales | 0.31 | 0.46 | 0.62 | 0.62 | 1.01 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 187.19 | 82.97 | -5.49 | 109.31 | 5.91 |
| Core EBITDA Growth(%) | 121.12 | 64.81 | 16.13 | -8.15 | -2.27 |
| EBIT Growth(%) | 261.99 | 895.12 | -24.17 | -76.15 | -26.51 |
| PAT Growth(%) | 486.99 | 299.10 | 428.31 | -92.29 | -12.12 |
| EPS Growth(%) | 134.79 | 299.10 | 428.30 | -92.29 | -12.12 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.20 | 0.21 | 0.63 | 0.52 | 0.39 |
| Current Ratio(x) | 1.25 | 1.28 | 2.28 | 2.07 | 2.77 |
| Quick Ratio(x) | 1.17 | 0.96 | 2.04 | 1.87 | 2.70 |
| Interest Cover(x) | 16.82 | 4.55 | 3.94 | 84.02 | 1,166.32 |
| Total Debt/Mcap(x) | 0.10 | 0.36 | 1.40 | 1.10 | 1.06 |
Compare Financial Ratios of peers of SHUKRA PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SHUKRA PHARMACEUTICALS | ₹507.9 Cr | 8.2% | 45.2% | 746.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹368,598.0 Cr | 2% | -0.3% | 59.8% | Stock Analytics | |
| CIPLA | ₹114,654.0 Cr | 6% | 2.8% | 50.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹104,348.0 Cr | 3.7% | 5.8% | 17.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹101,499.0 Cr | 2.6% | 7.9% | 94.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,429.4 Cr | -1.3% | -2.8% | 31.5% | Stock Analytics | |
SHUKRA PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SHUKRA PHARMACEUTICALS | 8.2% |
45.2% |
746.9% |
| SENSEX | 1.7% |
-0.8% |
19% |
You may also like the below Video Courses
